Accumulating studies have proven that lung cancers harboring oncogenic alterations in ROS1 or EML4-ALK respond poorly to immunotherapy (59), whereas KRAS mutations are associated with an improved response to immunotherapy (60). The gene discussed is EML4; the disease is lung carcinoma.